Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Diagnosing A Healthy US FDA: The MRI Drug Safety Review

Executive Summary

Do MRI contrast agents cause debilitating chronic illnesses in some patients who receive them? A group of patient advocates firmly believes they do. FDA’s approach to addressing the risk via a public advisory committee shows the agency has found an effective way to handle the type of safety scare that could have paralyzed it a decade ago.

You may also be interested in...



Warning Label For Gadolinium Contrast Agents Gets US FDA Panel Backing

Advisory committee agrees that risks of gadolinium retention in the brain and other organs need further study; actor Chuck Norris' wife was among several patients who testified of devastating medical problems following administration of agents.

Break-Point: FDA Committee Votes To Restrict Quinolones, But Does Not Endorse Disability Syndrome

An FDA advisory committee review of quinolone antibiotic safety focused on a very old safety issue – but points to a new era in antibiotic development, and restricted use models.

Who Needs Negotiation? US Rx Prices Are Falling – Thanks To Generics

A Congressional Budget Office review of prescription drug pricing trends over the past decade shows a surprising fact: the average costs per prescription in the US is falling. That probably won’t change the political debate over drug prices – but maybe it should.

Topics

UsernamePublicRestriction

Register

PS121601

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel